Cancer trial halted: did starting with immune drug first help beat tough breast cancer?
NCT ID NCT04770272
Summary
This study tested if giving an immunotherapy drug (atezolizumab) alone for two weeks before starting standard chemotherapy was better than starting both treatments together. It involved 442 people with triple-negative breast cancer, a hard-to-treat type, before they had surgery. The main goal was to see which approach led to more patients having no detectable cancer left after treatment and to find biological markers that predict who will respond best.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;
Bottrop, 46236, Germany
Conditions
Explore the condition pages connected to this study.